Category Archives: Technology

Preliminary results are in from the on-going international clinical study exploring the ability of OpsisDx to accurately identify people with multiple diseases.

Highlights:

1. OpsisDx distinguishes between people with cancer, hepatitis B viral and healthy controls
2. OpsisDx accurately identifies patient’s cancer tissue of origin (lung, prostate, breast, liver or colorectal)
3. Hepatitis B viral infection, often linked to increased likelihood for liver cancer, is observed as a distinct category from liver cancer patients
4. OpsisDx detects more stage I cancers than liquid biopsies as performed by GRAIL

Can OpsisDx distinguish between similar molecules? Let’s say between different salts or isomers of carrageenan or phenol vs cresol?

YES … we observe distinct NuTec profiles for each molecule or mixture, even for molecules with similar structures.

This provides a framework for people to better grasp the inner workings of OpsisDx.

We are obsessed with efficiency and committed to manufacturing in the U.S. all critical OpsisDx components.

Our NuTec Slide manufacturing team incorporates a new robot to the manufacturing process. This addition, plus updates to current automated manufacturing processes, more than quadruples our manufacturing capabilities. These updates set the ground work for future scale-up efforts.

Our team of scientists have completed a re-design of the NuTec Slide based on our continued research into this new field. This latest version offers increased reproducibility and stability. The generation 4 NuTec Slide will be used in an international, multi-disease study.

Thanks in no small part to core team member Dr. Tingjun Lei and his manufacturing team, Entopsis is now ISO certified (ISO 9001:2015 and ISO 13485:2016) to manufacture and sell medical devices.

Sarah Murray from The Financial Times wrote an article today on cancer diagnostics. Three technology platforms were discussed. The first was a breath-based technology developed by a students and researchers at MIT and Harvard Medical School. The second was Entopsis’s urine based Nutec profiling platform. And the third was a general discussion of liquid (blood) biopsies with comments by Professor Anirban Maitra from MD Anderson Cancer Center. Most current research is focused on liquid (i.e. blood) biopsies, especially in the context of detecting circulating nucleic acids or cells. Why has Entopsis chosen instead to work with urine? The strength

The Miami Herald just published an article about the relatively new healthcare startup economy in South Florida. Conventional wisdom motivates many healthcare startups to establish themselves in Boston and San Francisco. We at Entopsis are early to the game in Miami. Consider that Miami and its surrounding neighborhoods have a robust culture of disruption and improvisation. Here, being MacGyver is not a special skill. It’s a common survival trait hardwired by experience. Who has caught on to this fact? Not just smart investors like G3 Capital but also international investors. The Floridan winds have brought hungry MacGyvers and smart capital together to create the perfect storm and we have booked

Our dashing CFO, Dr. George Huang (see left), presents today at the CONVERGE Conference in Philadelphia! This conference is highly relevant because of the diverse representation of decision makers present, including insurers, startups, regulators, pharmaceuticals, hospital administrators and more. It’s rare to have such a broad spectrum of med tech related expertise in one place.

Entopsis is proud to support Dr. Kara Cavuoto’s research aimed at better understanding the microbiome of the pediatric eye.

The goal of our collaboration is to define the composition of the ocular surface microbial flora in children using novel culture-independent methods. Our hypothesis is that the microbiome of the ocular surface evolves with age. Additionally, we hypothesize that disruption of the normal ocular surface microbial community via antibiotics or other ocular therapies predisposes the eye to infection and disease. With the results of our pilot study, we will be able to create an ocular surface microbiome profile which would

Becton Dickinson (BD) just announced support for a few startups under the Breakout Labs program. In addition to a no-strings-attached grant, BD will provide expertise and resources where relevant to Entopsis. Ms. Lindy Fishburne from Breakout Labs commented that “Corporate partners usually wait until the end, and catch what comes out [of an accelerator program],” and that in contrast “BD is stepping in much earlier, because they understand that ‘white-space investing’ in technology is going to be critical going forward.” We at Entopsis are privileged and excited to be working with BD!